Indaptus Therapeutics is trading at $1.20, up 6.19% in after-hours trading after launching an amended $100 million at-the-market equity offering through H.C. Wainwright.

  • Regular-session close: $1.13.
  • The financing provides capital for development programs but creates potential dilution, likely driving heightened after-hours activity.
  • Broader markets were risk-off on September 1, 2026, making the financing announcement the clearest catalyst for the opposite-direction move.